Literature DB >> 7913694

Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive major histocompatibility complex class I antigen expression and cytokine-induced activation status.

M Ritter1, C Huber, J Auböck, H Pohl-Markl, J Troppmair, M Herold, A Gächter, W Nussbaumer, G Böck, D Nachbaur.   

Abstract

Cytotoxic T-cell lines (TCL) were raised in vitro using stimulator cells with a defined major histocompatibility complex (MHC) mismatch and tested in a cytotoxic chromium-release assay against haemopoietic and non-haemopoietic target cells from the original stimulator. Monoclonal antibody (mAb)-blocking experiments and simultaneous determination of MHC class I, class II, lymphocyte function-associated antigen-1 (LFA-1) and intracellular adhesion molecule-1 (ICAM-1) density by quantitative radioimmunometric methods and flow cytometry on target cells demonstrated that lysis was restricted by MHC class I and dependent upon the constitutive MHC class I antigen expression. Measurements showed a high constitutive expression of class I MHC antigens on peripheral blood mononuclear cells (PBMC), but a low one on keratinocytes (K). Also, PBMC were more susceptible to lysis by TCL than K. Interferon-gamma (IFN-gamma) treatment of K resulted in increased MHC class I antigen expression and enhanced lytic susceptibility to TCL. IFN-alpha and tumour necrosis factor-alpha (TNF-alpha) treatment, which did not modulate MHC class I antigen expression on K, did not influence the amount of K lysis either. None of the cytokines tested in this analysis, however, increased the expression of MHC class I, class II, ICAM-1 and LFA-1 on PBMC. Only IFN-gamma pretreatment showed a minimal, statistically significant increase in MHC class I antigen expression. In spite of the minimal effect of IFN-gamma and no effect of IFN-alpha on class I MHC expression, pretreatment of target cells with both cytokines considerably increased their lytic susceptibility. The mechanism of cytokine-induced enhanced lytic susceptibility to TCL was not explained by increased MHC class I, LFA-1 or ICAM-1 expression, since no correlation was found between surface expression of these molecules and lytic susceptibility to TCL. These data demonstrate that: (1) the constitutive density of MHC class I antigens determines the extent of TCL lysis; (2) IFN-gamma, and not IFN-alpha or TNF-alpha controls the amount of K target cell lysis by increasing their MHC class I antigen expression; and (3) IFN-gamma and IFN-alpha control the amount of PBMC target cell lysis by a mechanism independent of MHC class I, ICAM-1 or LFA-1 expression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7913694      PMCID: PMC1422367     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  42 in total

1.  Linear density gradient separation of human lymphocyte subsets. I. Analysis by mixed leukocyte culture and cell-mediated lympholysis responses.

Authors:  K S Zier; C Huber; H Braunsteiner
Journal:  Eur J Immunol       Date:  1977-06       Impact factor: 5.532

Review 2.  MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness.

Authors:  R M Zinkernagel; P C Doherty
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

3.  Growth of cultured human epidermal cells into multiple epithelia suitable for grafting.

Authors:  H Green; O Kehinde; J Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

4.  Radioimmunoassay for detection of changes in cell surface tumor antigen expression induced by interferon.

Authors:  J W Greiner; P Horan Hand; D Wunderlich; D Colcher
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

5.  Lymphocytes recognize human vascular endothelial and dermal fibroblast Ia antigens induced by recombinant immune interferon.

Authors:  J S Pober; T Collins; M A Gimbrone; R S Cotran; J D Gitlin; W Fiers; C Clayberger; A M Krensky; S J Burakoff; C S Reiss
Journal:  Nature       Date:  1983 Oct 20-26       Impact factor: 49.962

6.  The detailed distribution of MHC Class II antigens in normal human organs.

Authors:  A S Daar; S V Fuggle; J W Fabre; A Ting; P J Morris
Journal:  Transplantation       Date:  1984-09       Impact factor: 4.939

7.  Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells.

Authors:  D Wallach; M Fellous; M Revel
Journal:  Nature       Date:  1982-10-28       Impact factor: 49.962

8.  Large granular lymphocytes: morphological studies.

Authors:  D Huhn; C Huber; G Gastl
Journal:  Eur J Immunol       Date:  1982-11       Impact factor: 5.532

9.  Interferon enhances the susceptibility of virus-infected fibroblasts to cytotoxic T cells.

Authors:  J F Bukowski; R M Welsh
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

10.  Human autologous mixed lymphocyte reactivity is primarily specific for xenoprotein determinants adsorbed to antigen-presenting cells during rosette formation with sheep erythrocytes.

Authors:  C Huber; M Merkenschlager; C Gattringer; I Royston; U Fink; H Braunsteiner
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

View more
  3 in total

1.  Control of B-cell lymphoma by therapeutic vaccination and acquisition of immune resistance is independent of direct tumour IFN-gamma signalling.

Authors:  Rory Rearden; Amelia Sah; Brianna Doff; Takumi Kobayashi; Sara J McKee; Graham R Leggatt; Stephen R Mattarollo
Journal:  Immunol Cell Biol       Date:  2016-01-20       Impact factor: 5.126

Review 2.  Regulation of tumor growth by IFN-gamma in cancer immunotherapy.

Authors:  G L Beatty; Y Paterson
Journal:  Immunol Res       Date:  2001       Impact factor: 4.505

3.  Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells.

Authors:  J G Krueger; J T Wolfe; R T Nabeya; V P Vallat; P Gilleaudeau; N S Heftler; L M Austin; A B Gottlieb
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.